Dalacin C 150 mg (Clindamycin)

Product Overview

Dalacin C 150 mg is a prescription antibiotic that contains clindamycin phosphate as the active pharmaceutical ingredient. It is produced by Pfizer India Ltd, a globally recognized manufacturer with a strong track record in high‑quality pharmaceuticals. Each strip of Dalacin C includes ten hard gelatin capsules, each delivering exactly 150 mg of clindamycin. The product is marketed in three pack sizes — 30 capsules, 60 capsules, and 90 capsules — to accommodate varying treatment durations and patient needs. This flexibility allows clinicians to prescribe the precise quantity required for a full therapeutic course, reducing the risk of incomplete therapy and supporting antibiotic stewardship.

What is Dalacin C 150 mg (Clindamycin)

Clindamycin belongs to the lincosamide class of antibiotics and functions by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting the translocation step of protein synthesis. This mechanism results in a bacteriostatic effect that becomes bactericidal against rapidly multiplying organisms. The drug exhibits activity against a broad spectrum of Gram‑positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus species, as well as many anaerobic organisms such as Bacteroides fragilis, Clostridium difficile, and Peptococcus. Because of its potency against anaerobes, Dalacin C is frequently selected for infections that involve a mixed aerobic‑anaerobic flora, such as intra‑abdominal abscesses and periodontal disease.

Uses and Benefits

The therapeutic applications of Dalacin C are extensive. Clinicians often prescribe it when a patient has a documented penicillin allergy, when bacterial isolates demonstrate resistance to first‑line agents, or when the infection is known to be caused by anaerobic bacteria. The medication is indicated for:

• Skin and soft‑tissue infections, including cellulitis, abscesses, and post‑surgical wound infections
• Respiratory tract infections such as community‑acquired pneumonia and empyema
• Intra‑abdominal infections, including perforated appendicitis and diverticulitis
• Bone and joint infections (osteomyelitis) when caused by susceptible organisms
• Dental infections, particularly periodontitis and odontogenic abscesses
• Gynecologic infections, such as bacterial vaginosis and pelvic inflammatory disease
• Certain opportunistic infections in immunocompromised patients

Benefits of using Dalacin C include its reliable bactericidal activity, ability to penetrate deep tissue and bone, and effectiveness in polymicrobial environments. Additionally, the medication is available in multiple pack sizes, allowing patients to obtain the exact number of capsules needed for a complete course, which is crucial for preventing recurrence and combating antimicrobial resistance.

How It Works

Upon oral administration, clindamycin is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within one to two hours. The drug is extensively distributed into body fluids, including synovial fluid, abscess fluid, and bone, which explains its efficacy in treating deep‑seated infections. Metabolism of clindamycin occurs primarily via hepatic oxidation, producing an inactive metabolite that contributes minimally to overall antibacterial activity. Approximately 90 percent of the drug is eliminated through hepatic pathways, with a minor fraction excreted unchanged in the urine. The elimination half‑life averages four to five hours, supporting dosing intervals of six to eight hours for most adult regimens.

For a comprehensive scientific review of clindamycin pharmacokinetics and pharmacodynamics, consult the PubMed Central article on clindamycin disposition. Understanding these properties helps clinicians predict drug interactions, adjust dosing in renal or hepatic impairment, and monitor therapeutic outcomes.

Dosage Guidelines

Standard adult dosing for Dalacin C 150 mg typically involves one capsule taken every six to eight hours, depending on the severity of the infection and the site of involvement. A typical treatment course lasts seven to fourteen days, but the exact duration is determined by the prescribing clinician based on clinical response and microbiological findings. Patients should be instructed to swallow the capsule whole with a full glass of water to minimize gastrointestinal irritation.

In pediatric patients, the recommended dose is calculated per kilogram of body weight, generally ranging from 10 to 15 mg per kilogram per dose, administered every six hours. Dose adjustments are necessary for individuals with severe hepatic impairment (Child‑Pugh class C) or moderate to severe renal dysfunction, where the dosing interval may be extended to twelve hours. It is essential that dosage modifications are performed under medical supervision to avoid sub‑therapeutic exposure or increased toxicity.

Patients are reminded to complete the entire prescribed course, even if symptoms improve early, to ensure eradication of the pathogen and to reduce the risk of developing antibiotic‑resistant strains.

Side Effects

Like all pharmaceutical products, Dalacin C may produce adverse effects, most of which are mild and self‑limiting. The most frequently reported side effects include:

• Nausea, vomiting, and abdominal discomfort
• Diarrhea, which may range from mild to watery
• Metallic taste or oral thrush
• Skin manifestations such as rash, itching, or urticaria

Although uncommon, serious adverse events can occur. The most clinically significant is Clostridioides difficile‑associated colitis, a potentially life‑threatening condition characterized by severe diarrhea, abdominal cramping, and fever. If diarrhea persists beyond 24 hours, becomes bloody, or is accompanied by systemic signs, immediate medical evaluation is recommended. Other rare but noteworthy reactions include hypersensitivity pneumonitis, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic enzyme elevations. Patients with a history of inflammatory bowel disease should discuss the risks with their physician before initiating therapy.

Warnings and Precautions

Prior to prescribing Dalacin C, healthcare providers should obtain a thorough medical history, focusing on:

• Known hypersensitivity to clindamycin, lincomycin, or other lincosamide antibiotics
• Previous episodes of antibiotic‑associated colitis or C. difficile infection
• Severe hepatic disease, especially cirrhosis, or significant renal impairment
• Concurrent use of neuromuscular blocking agents, which may increase the risk of muscle weakness
• Pregnancy, breastfeeding, or plans for conception, as the safety profile in these populations requires careful assessment

Dalacin C should be used with caution in patients with a history of severe allergic reactions, as cross‑reactivity with other antibiotics is possible. Additionally, the medication may interact with certain antiretroviral agents, anticoagulants, and medications that affect hepatic enzyme activity. For detailed prescribing information, refer to the official FDA product label and consult a qualified healthcare professional.

FAQs

• Question: Which infections are most appropriately treated with Dalacin C 150 mg?
  Answer: It is indicated for serious Gram‑positive and anaerobic bacterial infections, including skin and soft‑tissue infections, respiratory tract infections, intra‑abdominal abscesses, dental infections, and certain bone or joint infections when susceptibility testing supports its use.
• Question: How should Dalacin C be stored to maintain potency?
  Answer: Store the capsules in their original packaging at room temperature, away from moisture, heat, and direct sunlight. Do not use after the printed expiration date, and keep the medication out of reach of children.
• Question: Can Dalacin C be taken with food or other medications?
  Answer: The drug can be taken with or without food, but administering it with a full glass of water helps reduce stomach upset. Patients should inform their physician of all concurrent medications, especially those that affect liver enzymes or have known interactions with clindamycin.
• Question: Is Dalacin C safe for use during pregnancy or while breastfeeding?
  Answer: Use should be limited to cases where the expected benefit justifies the potential risk. Animal studies have not demonstrated teratogenicity, but human data are limited. Breastfeeding mothers should discuss the risks with their healthcare provider, as small amounts of clindamycin can be excreted in milk.
• Question: Where can I find reliable information about clindamycin and its proper use?
  Answer: Trusted consumer resources include MedlinePlus, while professional literature can be accessed through the NIH, PubMed, and the FDA website.

Related Products

• Co-Trimoxazole 480 mg (Sulfamethoxazole/Trimethoprim)
• Dalacin C (Clindamycin)
• Dalacin C 300 mg (Clindamycin)
• Claribid 250 mg (Clarithromycin)
• Claribid (Clarithromycin)
• Oframax (Ceftriaxone)
• Phexin (Cephalexin)
• Claribid 500 mg (Clarithromycin)
• Oframax 500mg Injection (Ceftriaxone)
• Oframax 1gm Injection (Ceftriaxone)
• Phexin 250 mg (Cephalexin)
• Phexin 500 mg (Cephalexin)